DGAP-News: Nanostart subsidiary MagForce Nanotechnologies receives EU regulatory approval for its Nano-Cancer(R) therapy
(firmenpresse) - Nanostart AG / Miscellaneous
28.06.2010 07:44
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- Approved for use throughout EU as first-line therapy
- for all types of primary brain tumors
- 'Historic moment after more than 20 years of development'
- European market launch to commence in the coming weeks
Frankfurt / Berlin, June 28, 2010 - Following more than 20 years of
research and development efforts, MagForce Nanotechnologies AG, a
majority-owned subsidiary of Nanostart AG (Frankfurt Stock Exchange: MF6),
has received regulatory approval
for medical use of its Nano-Cancer(R) therapy throughout the European
Union. This momentous event marks the world's first nanoparticle-based
cancer treatment to come to market.
Approval was granted not just for treating one particular type of brain
tumor but rather, without limitation, for the treatment of all primary
brain tumors. Furthermore, the therapy was approved as a primary therapy,
meaning that it - like surgical resection, chemotherapy, and radiation -
may be used as a first-line treatment for patients who have been newly
diagnosed with brain tumors.
This novel therapy involves the instillation directly into the tumor of a
fluid containing special iron oxide nanoparticles. These magnetic
nanoparticles are then subjected to a controlled magnetic field so that
they oscillate and generate heat. The elevated temperature within the tumor
causes the cancer cells to be damaged or destroyed.
This approval follows successful completion of the conformity evaluation
procedure of the company's NanoTherm(R) magnetic fluid by Medcert GmbH and
of its NanoActivator(R) magnetic field applicator by Berlin Cert GmbH. Both
of these medical certification and testing companies are officially
authorized centers for the conformity evaluation of medical devices.
'With regulatory approval now received, our company has entered a new
phase. MagForce is transforming itself from a medical R&D company to a
commercial provider of medical technology,' said Dr. Peter Heinrich, CEO of
MagForce Nanotechnologies.
MagForce founder and CSO Dr. Andreas Jordan added, 'After research and
development efforts spanning more than 20 years, we now have regulatory
approval in hand. This is a historic moment for us.'
This regulatory approval gives the green light for the company to proceed
with its planned market launch of Nano-Cancer(R) therapy, which will
commence in the coming weeks.
Nanostart CEO Marco Beckmann underscored that 'regulatory approval was
granted not just for glioblastoma but for the treatment of all primary
brain tumors, thus opening enormous market potential for the new therapy.
We congratulate the management team and entire staff at MagForce on this
tremendous success.'
The regulatory approval was received based on the results of a clinical
study in patients suffering from recurrent glioblastoma, a particularly
aggressive and deadly form of brain tumor. In these clinical trials, the
new therapy was able to demonstrate its remarkable effectiveness, with
median patient survival time increased from 6.2 months using conventional
therapies to 13.4 months using Nano-Cancer(R) therapy in combination with
radiotherapy. Median patient survival following diagnosis of the
recurrence was thus more than doubled. Furthermore, compared to existing
conventional treatments, the side effects and patient discomfort associated
with the new therapy are minimal.
About Nanostart:
Nanostart AG is the world's leading nanotechnology investment company. The
Frankfurt-based company provides venture capital financing for
nanotechnology companies in various growth phases. It also provides the
benefits of its experience and expertise to developers of financial
instruments and to investors in the nanotechnology sector. For further
information about the company, please visit www.nanostart.de.
About MagForce Nanotechnologies:
MagForce Nanotechnologies AG is a world-leading company in the area of
nanotechnology-based cancer treatment. The proprietary procedure which it
has developed, Nano-Cancer(R) therapy, enables the targeted treatment of
solid tumors through the intratumoral release of heat from magnetic
nanoparticles. Its products used in the therapy, NanoTherm(R) and
NanoActivator(R), have received EU-wide regulatory approval as medical
devices for the treatment of brain tumors. For further information, visit
www.magforce.com.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of
offers to purchase or subscribe to securities. There will be no public
offering of securities of Nanostart AG in conjunction with the existing
listing of its shares in the 'Entry Standard' segment of the regulated
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This
notice does not constitute a securities prospectus. Neither this notice nor
the information contained within is intended for direct or indirect
distribution within the United States of America, Canada, Australia or
Japan.
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail: presse(at)nanostart.de
28.06.2010 07:44 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Datum: 28.06.2010 - 07:44 Uhr
Sprache: Deutsch
News-ID 23071
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 295 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Nanostart subsidiary MagForce Nanotechnologies receives EU regulatory approval for its Nano-Cancer(R) therapy"
steht unter der journalistisch-redaktionellen Verantwortung von
Nanostart AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
